Bixalomer vs Colestilan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Phosphate binder · full Chronic Kidney Disease pipeline

Bixalomer · Kiklin

Marketed by Astellas Pharma under a licence from Amgen

Phase 3 in Chronic Kidney Diseasesmall molecule
Weak signal

NCT00892749 · Phase 3 · completed

The study enrolled 248 participants but was open-label, single-arm, and had no placebo or active comparator, so it could not provide a controlled comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Change from baseline in serum phosphorus level at the end of treatment (Baseline and Week 12 or treatment discontinuation): Change in serum phosphorus, baseline to end of treatment (12 weeks): bixalomer -0.78 mg/dL (95% CI -0.98, -0.57) vs placebo 0.20 mg/dL (95% CI -0.00, 0.41); mean difference -0.98 mg/dL (95% CI -1.27, -0.69), P < 0.001. (met)

Result source: NCT01742585

Colestilan · Cholebine / BindRen

Marketed by Fuji Pharma Co., Ltd. and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT00542815 · Phase 3 · completed

This open-label, non-randomized, flexible-dose Phase III extension study gave colestilan (MCI-196) for up to 52 weeks to 632 dialysis patients with hyperphosphataemia who came from earlier colestilan studies, with a sevelamer group carried over from study E07. It was designed as a long-term safety study, and its phosphorus outcome is descriptive with no formal between-group test, so there is no met or missed result. Source: CT.gov posted results.

Reported efficacy

The Change in Serum Phosphorus for MCI-196 and Sevelamer (52 weeks (Baseline-52 weeks)): Primary outcome, change in serum phosphorus from baseline to week 52 in an open-label long-term safety study (no comparator test): -1.23 mg/dL (colestilan from E07/E08), -1.47 mg/dL (colestilan from E07) and -2.26 mg/dL (sevelamer from E07) (CT.gov posted results). (not_applicable)

Result source: NCT00542815

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBixalomerColestilan
Kidney composite outcome—Not posted · NCT01742585—Not posted · NCT00506441
UACR, % change—Not posted · NCT01742585—Not posted · NCT00506441
eGFR slope—Not posted · NCT01742585—Not posted · NCT00506441
Haemoglobin, change—Not posted · NCT01742585—Not posted · NCT00506441

Kidney composite outcome

Bixalomer
—Not posted · NCT01742585
Colestilan
—Not posted · NCT00506441

UACR, % change

Bixalomer
—Not posted · NCT01742585
Colestilan
—Not posted · NCT00506441

eGFR slope

Bixalomer
—Not posted · NCT01742585
Colestilan
—Not posted · NCT00506441

Haemoglobin, change

Bixalomer
—Not posted · NCT01742585
Colestilan
—Not posted · NCT00506441
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Bixalomer: 1 of 5 rows · Colestilan: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBixalomerColestilan
Serum Phosphorus Change mg/dL
absolute change · mg/dL
-0.78 vs 0.2 placebo mg/dL @ 12wka,b,c
NCT01742585 · Phase 3 · sponsor-reported, not registry data
-1.23 vs -2.26 Sevelamer mg/dL @ 52wkd,a,b,c
NCT00542815 · Phase 3
show 1 more dose
-1.47 vs -2.26 Sevelamer mg/dL @ 52wk
NCT00542815 · Phase 3
Dropout rate—
24.5%MCI-196 From E07 / E08 Studiese
NCT00542815 · Phase 3
show 17 more results
42.1%MCI-196 From E07 Study
NCT00542815 · Phase 3
—MCI-196 From E07/E08 Studies
NCT00542815 · Phase 3
36.4%MCI-196 (Open-label Period)
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
—MCI-196 (Placebo-Controlled Period
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
—MCI-196 (Placebo-controlled Withdr
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
—MCI-196 (Double-blind Period)
NCT00506441 · Phase 3 · monotherapy
—MCI-196 (Open-label Period)
NCT00506441 · Phase 3 · monotherapy
47.4%
NCT00772382 · Phase 3 · registry result, not featured evidence
18.9%MCI-196 (Active) + Simvastatin (Pl
NCT00858637 · Phase 3 · registry result, not featured evidence · combination
—MCI-196 (Active) + Simvastin (Plac
NCT00858637 · Phase 3 · registry result, not featured evidence · combination
39.2%15 g
NCT00542386 · Phase 3 · registry result, not featured evidence
36.9%12 g
NCT00542386 · Phase 3 · registry result, not featured evidence
33.3%9 g
NCT00542386 · Phase 3 · registry result, not featured evidence
27.5%6 g
NCT00542386 · Phase 3 · registry result, not featured evidence
41.3%3 g
NCT00542386 · Phase 3 · registry result, not featured evidence
—Candesartan Plus Colestilan (Day 7
NCT01976572 · Phase 1 · registry result, not featured evidence · combination
—Colestilan Alone (Day 3 to 6)
NCT01976572 · Phase 1 · registry result, not featured evidence · monotherapy
Discontinued due to AEs—
4.4%MCI-196 From E07 / E08 Studiese
NCT00542815 · Phase 3
show 17 more results
7.9%MCI-196 From E07 Study
NCT00542815 · Phase 3
—MCI-196 From E07/E08 Studies
NCT00542815 · Phase 3
17%MCI-196 (Open-label Period)
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
—MCI-196 (Placebo-Controlled Period
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
—MCI-196 (Placebo-controlled Withdr
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
—MCI-196 (Double-blind Period)
NCT00506441 · Phase 3 · monotherapy
—MCI-196 (Open-label Period)
NCT00506441 · Phase 3 · monotherapy
16.4%
NCT00772382 · Phase 3 · registry result, not featured evidence
11%MCI-196 (Active) + Simvastatin (Pl
NCT00858637 · Phase 3 · registry result, not featured evidence · combination
—MCI-196 (Active) + Simvastin (Plac
NCT00858637 · Phase 3 · registry result, not featured evidence · combination
12.7%15 g
NCT00542386 · Phase 3 · registry result, not featured evidence
7.8%12 g
NCT00542386 · Phase 3 · registry result, not featured evidence
7.1%9 g
NCT00542386 · Phase 3 · registry result, not featured evidence
6.9%6 g
NCT00542386 · Phase 3 · registry result, not featured evidence
1%3 g
NCT00542386 · Phase 3 · registry result, not featured evidence
—Candesartan Plus Colestilan (Day 7
NCT01976572 · Phase 1 · registry result, not featured evidence · combination
—Colestilan Alone (Day 3 to 6)
NCT01976572 · Phase 1 · registry result, not featured evidence · monotherapy
Serious AEs—
—MCI-196 From E07 / E08 Studiese
NCT00542815 · Phase 3
show 17 more results
40.8%MCI-196 From E07 Study
NCT00542815 · Phase 3
17.1%MCI-196 From E07/E08 Studies
NCT00542815 · Phase 3
16%MCI-196 (Open-label Period)
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
4%MCI-196 (Placebo-Controlled Period
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
—MCI-196 (Placebo-controlled Withdr
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
11.6%MCI-196 (Double-blind Period)
NCT00506441 · Phase 3 · monotherapy
15.1%MCI-196 (Open-label Period)
NCT00506441 · Phase 3 · monotherapy
54.3%
NCT00772382 · Phase 3 · registry result, not featured evidence
12.5%MCI-196 (Active) + Simvastatin (Pl
NCT00858637 · Phase 3 · registry result, not featured evidence · combination
—MCI-196 (Active) + Simvastin (Plac
NCT00858637 · Phase 3 · registry result, not featured evidence · combination
5%15 g
NCT00542386 · Phase 3 · registry result, not featured evidence
6.9%12 g
NCT00542386 · Phase 3 · registry result, not featured evidence
2%9 g
NCT00542386 · Phase 3 · registry result, not featured evidence
1%6 g
NCT00542386 · Phase 3 · registry result, not featured evidence
2.9%3 g
NCT00542386 · Phase 3 · registry result, not featured evidence
0%Candesartan Plus Colestilan (Day 7
NCT01976572 · Phase 1 · registry result, not featured evidence · combination
0%Colestilan Alone (Day 3 to 6)
NCT01976572 · Phase 1 · registry result, not featured evidence · monotherapy
Most frequent reported AEs—
e
hypertension 30.3%
diarrhoea 19.7%
vomiting 19.7%
NCT00542815 · Phase 3
show 14 more results
hypertension 12.7%
nausea 11.6%
dyspepsia 9.3%
NCT00542815 · Phase 3
vomiting 16.7% (placebo 0%)
diarrhoea 13% (placebo 1.9%)
nausea 9.3% (placebo 1.9%)
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
haemodialysis-induced symptom 6% (placebo 0%)
bronchitis 4% (placebo 1.9%)
constipation 4% (placebo 0%)
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
nausea 4.7% (placebo 0%)
arthralgia 3.5% (placebo 1.2%)
diarrhoea 3.5% (placebo 3.6%)
NCT00506441 · Phase 3 · monotherapy
diarrhoea 9% (placebo 3.6%)
nausea 8.6% (placebo 0%)
vomiting 7.3% (placebo 0%)
NCT00506441 · Phase 3 · monotherapy
nausea 22.4%
vomiting 20.7%
diarrhoea 19.8%
NCT00772382 · Phase 3 · registry result, not featured evidence
headache 9.4%
anaemia 8.6%
dyspepsia 7.8%
NCT00858637 · Phase 3 · registry result, not featured evidence · combination
15 g
nausea 19.8% (placebo 0%)
dyspepsia 8.9% (placebo 0.8%)
abdominal distension 5.9% (placebo 3%)
NCT00542386 · Phase 3 · registry result, not featured evidence
12 g
nausea 18.6% (placebo 0%)
vomiting 10.8% (placebo 1.5%)
abdominal distension 6.9% (placebo 3%)
NCT00542386 · Phase 3 · registry result, not featured evidence
9 g
nausea 12.2% (placebo 0%)
vomiting 8.2% (placebo 1.5%)
dyspepsia 7.1% (placebo 0.8%)
NCT00542386 · Phase 3 · registry result, not featured evidence
6 g
nausea 8.8% (placebo 0%)
dyspepsia 7.8% (placebo 0.8%)
hypertension 5.9% (placebo 3%)
NCT00542386 · Phase 3 · registry result, not featured evidence
3 g
diarrhoea 4.8% (placebo 5.3%)
asthenia 3.8% (placebo 0.8%)
dyspepsia 3.8% (placebo 0.8%)
NCT00542386 · Phase 3 · registry result, not featured evidence
dizziness 11.1%
fatigue 11.1%
headache 11.1%
NCT01976572 · Phase 1 · registry result, not featured evidence · combination
fatigue 11.1%
headache 11.1%
nausea 11.1%
NCT01976572 · Phase 1 · registry result, not featured evidence · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 12 weeks versus 52 weeks.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for 15 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Colestilan

LDL-C -26.22% (n=429) vs -28.66% (n=124) Sevelamer @ 52wk
percent change · % of baseline
NCT00542815 · Phase 3
show 1 more result
-30.62% (n=75) vs -28.66% (n=124) Sevelamer @ 52wk
NCT00542815 · Phase 3
Serum Phosphorus -1.41 vs -0.12 placebo mg/dL @ 12wk15 g
absolute change · mg/dL
NCT00542386 · Phase 3 · registry result, not featured evidence
show 7 more results
-0.71 vs -0.12 placebo mg/dL @ 12wk12 g
NCT00542386 · Phase 3 · registry result, not featured evidence
-0.97 vs -0.12 placebo mg/dL @ 12wk9 g
NCT00542386 · Phase 3 · registry result, not featured evidence
-0.77 vs -0.12 placebo mg/dL @ 12wk6 g
NCT00542386 · Phase 3 · registry result, not featured evidence
-0.23 vs -0.12 placebo mg/dL @ 12wk3 g
NCT00542386 · Phase 3 · registry result, not featured evidence
-0.24 vs 1.27 placebo mg/dL @ 16wk
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
-1.12 vs -2.16 Sevelamer mg/dL @ 12wk
NCT00416520 · Phase 3 · Chronic Kidney Disease, Hyperphosphatemia · phase 3
-0.04 vs 0.71 placebo mg/dL @ 16wk
NCT00506441 · Phase 3 · monotherapy
Serum Phosphorus -1.54 mg/dL @ 12wk
absolute change · mg/dL
No placebo or comparator arm
NCT00506441 · Phase 3 · monotherapy
show 1 more result
-1.18 mg/dL @ 52wk
NCT00772382 · Phase 3 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bixalomer's landscape · Colestilan's landscape